Scribe Therapeutics raises $129M in its gene editing IPO
Scribe Therapeutics has raised approximately $129 million through an initial public offering (IPO), marking the first such event for a developer of gene-editing medicines since early 2024. The company sold 8.58 million shares at $15 each, exceeding earlier projections and with plans to trade under the ticker symbol 'SCTX' on Nasdaq starting Friday. The biotech IPO market has been gaining momentum in 2026, with Scribe's offering being one of several large-scale public debuts. While most recent offerings have come from more mature companies with drugs in mid- or late-stage trials, Scribe is earlier in its development and focuses on epigenetic approaches to treat common cardiometabolic diseases. Scribe’s lead candidate, STX-1150, targets the PCSK9 protein to lower LDL-C cholesterol. The company aims for long-lasting effects without permanently altering DNA and expects first-in-human trial data by mid-2027.
Tickers: $MGX
Topics: biotech gene editing IPO Scribe Therapeutics